Short stature can be a severe side-effect of bone marrow transplantation (BMT). Because of the effect of weight changes on growth rate and on plasma insulin-like growth factor (IGF I), we analyzed changes in height and body mass index (BMI) in 53 patients given BMT. Group 1 (n = 22) was given 12 Gy total body irradiation (TBI) as six fractions, group 2 (n = 14) 10 Gy TBI (one dose), group 3 (n = 8) 6 Gy total lymphoid irradiation (one dose), and group 4 (n = 9) chemotherapy alone. At the first evaluation, 13/36 patients in groups 1 and 2 had low growth hormone (GH) peaks after stimulation. The mean plasma IGF I concentrations (z score) were similar in groups 1 (−2.9 ± 0.3) and 2 (−2.5 ± 0.3), and in groups 3 (−1.4 ± 0.3) and 4 (−1.4 ± 0.7), but those of group 1 were lower than those of groups 3 (P Ͻ 0.01) and 4 (P Ͻ 0.05), and those of group 2 than those of group 3 (P Ͻ 0.05). BMI during the 5 years after BMT did not change in groups 1 and 2, decreased in group 3, and increased in group 4. However, these changes were not significant. Most of the patients given TBI had BMI below the mean at 2 (66%) and 5 (57%) years later. Their BMI and leptin concentrations correlated positively with each other (P = 0.005), and negatively with GH peak (P = 0.02 for BMI and 0.007 for leptin). In conclusion, this study suggests that TBI actually decreases GH secretion and is followed by a persistent low BMI. The negative relationship between GH peak and leptin may indicate that both are markers of a TBIinduced hypothalamic-pituitary lesion. Bone Marrow Transplantation (2000) 26, 1205-1210. Keywords: bone marrow transplantation; body irradiation; body mass index; growth; growth hormone; leptin Short stature can be a severe side-effect of bone marrow transplantation (BMT). It may be caused by the initial disease and its treatment before BMT, by the conditioning protocol used for BMT, particularly the irradiation, by the complications of the BMT, and/or by the long-term corticosteroid therapy required to treat these complications. The irradiation may cause short stature in two ways: in patients given total body irradiation (TBI), hypothalamic-pituitary irradiation may decrease the secretion of growth hormone (GH); patients given TBI or total lymphoid irradiation (TLI) may suffer from bone lesions.
complications of the BMT, and/or by the long-term corticosteroid therapy required to treat these complications. The irradiation may cause short stature in two ways: in patients given total body irradiation (TBI), hypothalamic-pituitary irradiation may decrease the secretion of growth hormone (GH); patients given TBI or total lymphoid irradiation (TLI) may suffer from bone lesions. 1 These lesions may be responsible for resistance to insulin-like growth factor I (IGF I), the secretion of which depends on GH and nutritional state, and a poor growth response to GH therapy. 2 The fall in weight following TBI in some patients, the effect of weight changes on growth rate and plasma IGF I, 3 and the very short adult height in many patients given TBI have prompted us to analyze the factors influencing changes in height and body mass index (BMI). We have done this by comparing patients given different conditioning protocols for BMT. Our aims were to determine if TBI actually decreases GH secretion, and if there is any relationship between the conditioning protocol and changes in BMI and plasma leptin concentrations.
Materials and methods

Patients
Fifty-three patients (34 of them boys) given BMT before their 10th year (girls) or 12th year (boys) were followed in the Pediatric Endocrinology Department, at Hôpital Necker-Enfants Malades, Paris. None of them had any central nervous system involvement, or had been given additional irradiation. All were in remission without complications, and none had received long-term corticosteroid therapy. Fifty-eight other patients who satisfied these criteria were excluded because of factors other than conditioning for BMT which might have interfered with their growth. These factors were associated disease (thalassemia major, n = 2; diabetes mellitus, n = 1; chronic diarrhea, n = 4; scoliosis, n = 3) or BMT complications (long-term corticosteroid therapy, n = 5; chronic graft-versus-host disease, n = 21; hemolytic anemia, n = 2; hepatic disease, n = 11; pulmonary disease, n = 5; renal insufficiency, n = 4). Eight patients were followed elsewhere. Patients were categorized in four groups according to the conditioning protocol they had received (Table 1) : group 1 (n = 22) received 12 Gy TBI as six fractions of 2 Gy within 3 con- h P = 0.003 compared with group 1, P = 0.004 compared with group 2 and P = 0.04 compared with group 4. NA = not available. secutive days; group 2 (n = 14) 10 Gy TBI; group 3 (n = 8) 6 Gy TLI as single 4 h exposures; and group 4 (n = 9) chemotherapy alone. Patients in group 1 were irradiated with a 5.5 mV linear accelerator at 50 cGy/min, and those in groups 2 and 3 with an 18 mV linear accelerator at 4.2 cGy/min.
Protocol
All patients and their parents gave informed consent to the evaluations. The first and last evaluations were performed 3.3 ± 0.2 (2 to 9.2) years and 7.7 ± 0.4 (2 to 15.7) years after BMT. The first evaluation was performed in a single morning in a fasting state, and included determination of height, weight, pubertal stage, plasma free thyroxine, thyrotropin, IGF I (n = 51) and leptin (n = 52) concentrations. The IGF I and leptin concentrations of 10 patients were measured a second time at a different pubertal stage. In patients of pubertal age, and/or with spontaneous pubertal development, the basal plasma concentrations of gonadotropins and estradiol (in girls) or testosterone (in boys) were also measured. Patients given TBI (groups 1 and 2) also underwent a GH stimulation test. A second GH stimulation test was performed in 12 patients with a low GH peak, and also in 18 with a normal GH peak who continued to show a decreased growth rate despite normal thyroid hormone concentrations. Patients with high thyrotropin concentrations were given thyroxine replacement therapy (n = 26). Patients of pubertal age who had an uncompensated sex steroid deficiency (prepubertal estradiol or testosterone despite high plasma gonadotropin concentrations) were given oral ethinyl estradiol (cases 3, 20, 23, 24, 33; 2 g/day) or testosterone heptylate (cases 15, 32 and 36; 25 mg i.m. every 15 days) during their growing period. The criteria for GH therapy were a GH peak of less than 10 g/l after stimulation test, and a total height loss from BMT of 1 standard deviation (s.d.) or more, except for cases 1 and 27 who were treated despite a normal GH peak after two stimulation tests. GH (0.7 U/kg/week) was given to 16 patients on 6 days each week by subcutaneous injection.
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Height was measured using a Harpenden stadiometer and expressed as s.d. based on chronological age. 4 The BMI (weight in kilograms/height in meters squared) was expressed as a z score (zs). 5 Patients' target heights were calculated from mid-parental heights. 6 Adult height was considered to be reached when growth during the preceding year was less than 1 cm, with a bone age of 15 years in girls and 16 in boys. GH secretion was stimulated by a sequential arginine insulin test, and by an ornithine test at a second evaluation. The measurements were made using radioimmunoassay (RIA). Plasma IGF I (IGF-RIACT; Cis bio, Gif sur Yvette, France) was measured with a two-site monoclonal immunoradiometric assay (IRMA). Leptin (Linco Research, St Louis, MO, USA) was measured by RIA. The results are expressed as zs for IGF I and as multiples of the median (mom) for leptin to overcome the disparity in pubertal stages. 7 Data are means ± s.e.m. Changes in height and BMI were analyzed by a Wilcoxon signed rank test, and the differences between groups by a Kruskall-Wallis test followed by Mann-Whitney tests. Correlations were made with a Spearman rank test.
Results
GH peak and plasma IGF I
At the first evaluation, 13/36 patients in groups 1 and 2 had low GH peaks after stimulation ( Table 1 ). The GH peaks in the 30 patients tested twice, with an interval of 2.1 ± 0.2 years, were 12.2 ± 1.0 g/l at the first and 11.9 ± 1.4 g/l at the second evaluations (NS), and the GH peaks did not correlate (Figure 1) . In any given patient the GH peaks at these evaluations were concordant in 17 (normal in 11, low in six) and discordant in 13 patients. The mean plasma IGF I concentrations (zs) were similar in groups 1 (−2.9 ± 0.3) and 2 (−2.5 ± 0.3), and in groups 3 (−1.4 ± 0.3) and 4 (−1.4 ± 0.7). Those of group 1 were significantly lower than those of groups 3 (P Ͻ 0.01) and 4 (P Ͻ 0.05), and those of group 2 were lower than those of group 3 (P Ͻ 0.05).
The GH peaks and plasma IGF I concentrations did not correlate with each other, or with height changes since BMT. In the 13 patients given GH therapy for more than 1 year, the growth rate during the first year increased from 4.1 ± 0.4 to 6.1 ± 0.5 cm (P = 0.02).
BMI and plasma leptin
BMI during the 5 years after BMT did not change in groups 1 and 2, decreased in group 3, and increased in group 4 ( Figure 2 ), but these changes were not significant. At 2 and 5 years after TBI, 66% and 57%, respectively of patients had BMI below the mean. The changes in their BMI before GH therapy did not correlate with changes in height. The corresponding plasma leptin concentrations were signifi- Years after BMT cantly lower in group 3 than in each of the other groups ( Figure 3) . BMI correlated positively with these concentrations in the whole population (rho = 0.5, P = 0.0001) and in groups 2 (P = 0.004) and 4 (P Ͻ 0.05). In patients given TBI (groups 1 and 2), the BMI and leptin concentrations correlated positively with each other (rho = 0.435, P = 0.005), and negatively with the GH peak (rho = −0.4, P = 0.02 for BMI; rho = −0.416, p = 0.007 for leptin), but not with growth rate or plasma IGF I concentrations.
Adult height
In 15 patients (Figure 4 ), height at BMT (−0.3 ± 0.2 s.d.) was similar to the target height (0.2 ± 0.2 s.d.), but adult height (−1.2 ± 0.2 s.d.) was significantly lower than both height at BMT and target height (P Ͻ 0.01 for both). In the 12 patients not treated with GH, the height at onset of puberty (−0.6 ± 0.3 s.d.) was greater than adult height (−1.2 ± 0.2 s.d., P = 0.04). Their pubertal growth was 18.4 ± 2 cm in boys and 13.8 ± 1.9 cm in girls (NS).
Discussion
This study suggests that TBI actually decreases GH secretion, is followed by persistent low BMI, and interferes with leptin secretion. The negative relationship between the GH peak and the leptin concentrations is probably due to the opposite effects on them of the BMI, but it may also indicate that both are markers of TBI-induced hypothalamic-pituitary lesion.
Various findings suggest that GH secretion is actually decreased by TBI. Thus the plasma IGF I concentration, which depends on GH, was lower in the TBI group than in the TLI group (in whom the hypothalamic-pituitary area is not affected). It was also lower than in the group con- Table 1 ditioned with chemotherapy alone, despite similar BMIs. However, these concentrations in the patients given TBI did not correlate with the GH peaks, nor with height changes. In addition, the GH peaks at the first and the second evaluations were discordant in 13/30 cases. It is therefore difficult to claim that TBI induces GH deficiency for several reasons. First, the data accumulated after fractionated cranial irradiation are not useful because the effect of this type of irradiation is not comparable to that of a single high dose given as TBI. Second, other factors, particularly the bone irradiation associated with cranial irradiation, also contribute to the decreased growth rate by causing bone lesions. Lastly, these bone lesions may be
Bone Marrow Transplantation responsible for resistance to IGF I, whose plasma concentration increases, and so rules it out as a diagnostic tool for GH deficiency. Published data indicate that there is a reduction in the GH peak after a pharmacological stimulation test in 20-70% of patients given TBI who have had no previous cranial irradiation. 2, [8] [9] [10] [11] [12] That the bone lesions are responsible for the growth failure that follows body irradiation is suggested by the markedly decreased growth rate in some patients despite their normal endocrine function, 13 by the poor growth response to standard doses of GH after TBI-induced GH deficiency, and by skeletal abnormalities in children who have been given TBI, particularly those irradiated before they were 8 years old. 1 We found that GH therapy did not produce catch-up growth, but prevented any further loss of height by inducing normalization of the growth rate. The height changes between TBI and adult height (s.d.) were −0.9 in our study, and −1.37 in the 39 patients given fractionated TBI, −0.88 in the 39 given single dose TBI and −0.71 in the 17 given TLI. 14 The BMI of the patients given TBI did not change, while it increased in those given chemotherapy. However, these changes were not significant, and most of the patients given TBI had a BMI below the mean 2 and 5 years later. Cohen et al 15 evaluated BMI changes in 88 children 5 years after BMT, and found significant increases. They concluded that malnutrition and malabsorption do not seem to be a cause of decreased growth rate after BMT. The persistence of a lower than normal BMI after TBI differs from the data observed in patients given fractionated cranial irradiation, particularly for leukemia, whose BMI is frequently increased. 16, 17 This may be due to differing effects of TBI and fractionated cranial irradiation on the hypothalamicpituitary region, and/or to the irradiation of adipose tissue during TBI. The possible effect of a decreased BMI on growth rate and on plasma IGF I 3 and, to our knowledge, the absence of reported data on plasma leptin concentrations and their relationship to BMI and the GH peak after BMT, prompted us to evaluate the BMI and leptin concentrations according to the conditioning protocol. These concentrations were similar in patients given TBI and in those given chemotherapy, but these had higher BMIs. BMI and leptin concentrations correlated positively with each other and negatively with GH peaks, but not with growth rates or plasma IGF I concentrations. Kauppila et al 18 evaluated the GH response to GH-releasing hormone in adults given BMT and also found an inverse relationship between BMI and GH peak. The persistent low BMI after TBI and the poor growth response to standard doses of GH after TBIinduced GH deficiency suggest that nutritional support may be considered to optimize the growth rate of these patients.
